Evidence map›Paper›PMID 25417928›Full record

ReviewCNS neuroscience & therapeutics2014

Ketamine-an update on its clinical uses and abuses.

Jian Xu, Hong Lei

Abstract readReview
In one paragraph

Review in CNS neuroscience & therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Mitochondrial damage causes inflammation via cGAS-STING signaling in ketamine-induced cystitis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Ketamine, an Old-New Drug: Uses and Abuses.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  9. Review
  10. Review
  11. Article
  12. Advances in novel molecular targets for antidepressants.Progress in neuro-psychopharmacology & biological psychiatry · 2021
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jian XuDepartment of Laboratory Medicine, Chang Hai Hospital, Second Military Medical University, Shanghai, China.
Hong Lei

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review highlights the recent clinical research that supports the therapeutic utility of ketamine as a multifaceted drug. After long-term use as a dissociative anesthetic, it has re-emerged as a useful agent for ameliorating pain, asthmaticus, and depression. In addition, it is also a substance of abuse. Chronic ketamine abuse over prolonged periods (weeks, months, and years) can produce toxicity to the gastrointestinal and urinary tract. In this review, we described the recent progress on its clinical uses and abuses.

Indexed as

AnalgesicsAnimalsAsthmaGastrointestinal TractHumansKetamineMajor Depressive DisorderPainSubstance-Related DisordersSuicidal IdeationUrinary TractAnalgesicsKetamineAbuseAntidepressantAsthmaticusKetamine

Identifiers

PMID25417928
PMCPMC6493134

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.